Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Atreca

DB:0C1
Snowflake Description

Flawless balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
0C1
DB
$391M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Atreca, Inc., a biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. The last earnings update was 28 days ago. More info.


Add to Portfolio Compare Print
  • Atreca has significant price volatility in the past 3 months.
0C1 Share Price and Events
7 Day Returns
4.3%
DB:0C1
2.7%
DE Biotechs
2.1%
DE Market
1 Year Returns
-
DB:0C1
-9.8%
DE Biotechs
-16.6%
DE Market
0C1 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Atreca (0C1) 4.3% -43% -3.2% - - -
DE Biotechs 2.7% -5.6% -20.7% -9.8% 15.7% -11.9%
DE Market 2.1% -12.6% -22.9% -16.6% -21.9% -27.8%
1 Year Return vs Industry and Market
  • No trading data on 0C1.
  • No trading data on 0C1.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

0C1 Value

 Is Atreca undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Atreca. This is due to cash flow or dividend data being unavailable. The share price is €12.2.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Atreca's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Atreca's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:0C1 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-4.26
NasdaqGS:BCEL Share Price ** NasdaqGS (2020-04-07) in USD $13.92
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 43.27x
Germany Market PE Ratio Median Figure of 402 Publicly-Listed Companies 16.83x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Atreca.

DB:0C1 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:BCEL Share Price ÷ EPS (both in USD)

= 13.92 ÷ -4.26

-3.27x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Atreca is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Atreca is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Atreca's expected growth come at a high price?
Raw Data
DB:0C1 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -3.27x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts
-12.6%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.7x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.22x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Atreca, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Atreca's assets?
Raw Data
DB:0C1 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $6.68
NasdaqGS:BCEL Share Price * NasdaqGS (2020-04-07) in USD $13.92
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.31x
Germany Market PB Ratio Median Figure of 573 Publicly-Listed Companies 1.45x
DB:0C1 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:BCEL Share Price ÷ Book Value per Share (both in USD)

= 13.92 ÷ 6.68

2.08x

* Primary Listing of Atreca.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Atreca is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Atreca's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Atreca has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

0C1 Future Performance

 How is Atreca expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-12.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Atreca expected to grow at an attractive rate?
  • Unable to compare Atreca's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Atreca's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Unable to compare Atreca's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:0C1 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:0C1 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts -12.6%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 37.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.5%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:0C1 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:0C1 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 79 -64 -122 6
2023-12-31 18 -133 -171 6
2022-12-31 6 -90 -128 6
2021-12-31 4 -75 -110 6
2020-12-31 0 -77 -99 6
2020-04-08
DB:0C1 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 -59 -67
2019-09-30 -53 -59
2019-06-30 -45 -53
2019-03-31 -40 -44
2018-12-31 -35 -38
2017-12-31 -25 -28

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Atreca is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Unable to determine if Atreca is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:0C1 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below

All data from Atreca Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:0C1 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 -2.54 -0.79 -3.57 3.00
2023-12-31 -3.68 -3.25 -4.05 3.00
2022-12-31 -3.21 -2.72 -3.65 3.00
2021-12-31 -2.94 -2.32 -3.51 3.00
2020-12-31 -3.38 -3.20 -3.56 2.00
2020-04-08
DB:0C1 Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -4.26
2019-09-30 -6.35
2019-06-30 -18.88
2019-03-31 -20.77
2018-12-31 -18.02
2017-12-31 -13.14

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Atreca will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Atreca's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Atreca has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

0C1 Past Performance

  How has Atreca performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Atreca's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Atreca does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Atreca's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Atreca's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Atreca's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Atreca Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:0C1 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 -67.48 23.55 49.02
2019-09-30 -59.36 16.73 47.53
2019-06-30 -53.12 12.82 43.45
2019-03-31 -43.86 10.59 35.27
2018-12-31 -37.94 8.82 30.76
2017-12-31 -27.53 6.29 23.15

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Atreca has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Atreca has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Atreca improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Atreca's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Atreca has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

0C1 Health

 How is Atreca's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Atreca's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Atreca is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Atreca's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Atreca's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Atreca has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Atreca Company Filings, last reported 3 months ago.

DB:0C1 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 186.95 0.00 172.62
2019-09-30 205.00 0.00 201.04
2019-06-30 218.88 0.00 219.66
2019-03-31 104.30 0.00 100.66
2018-12-31 117.02 0.00 114.50
2017-12-31 33.14 0.00 30.61
  • Atreca has no debt.
  • Atreca has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Atreca has sufficient cash runway for 2.8 years based on current free cash flow.
  • Atreca has sufficient cash runway for 2.6 years if free cash flow continues to grow at historical rates of 39.2% each year.
X
Financial health checks
We assess Atreca's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Atreca has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

0C1 Dividends

 What is Atreca's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Atreca dividends.
If you bought €2,000 of Atreca shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Atreca's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Atreca's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:0C1 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 314 Stocks 3.7%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 4.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:0C1 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-04-08

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Atreca has not reported any payouts.
  • Unable to verify if Atreca's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Atreca's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Atreca has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Atreca's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Atreca afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Atreca has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

0C1 Management

 What is the CEO of Atreca's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
John Orwin
COMPENSATION $4,615,532
AGE 54
TENURE AS CEO 2 years
CEO Bio

Mr. John A. Orwin has been President, Chief Executive Officer and Director at Atreca, Inc. since April 19, 2018 Mr. Orwin has been a Director of Relypsa, Inc since June 2013 and Seattle Genetics, Inc. since January 13, 2014. Prior to joining Atreca, Mr. Orwin served as the Chief Executive Officer of Relypsa, Inc. since June 17, 2013 until June 30, 2017 and served as its President since June 2013 until March 31, 2017. Mr. Orwin is a biotechnology and pharmaceutical industry veteran with executive-level experience at publicly-held and private biotechnology and large pharmaceutical companies, including significant experience in commercial launch and sales support. He served as the Chief Executive Officer of Affymax, Inc. since February 1, 2011 until May 15, 2013. Mr. Orwin served as the President and Chief Operating Officer at Affymax, Inc. from joining it in April 2010 to January 2011. Mr. Orwin served as Senior Vice President of Sales & Marketing for Bio Oncology of Genentech, Inc. since January 17, 2007 until 2010. Mr. Orwin served as Vice President of Bio Oncology at Genentech, Inc. until January 17, 2007. He served as a Vice President of Human EGF-Receptor Family Product Sales and Marketing at Genentech, Inc. since December 2004. He was responsible for leadership and development of the Human EGF-Receptor family product portfolio, including sales and marketing activities and the business's life cycle plans. From January 2005 to April 2010, Mr. Orwin served at Genentech. From 2001 to 2004, Mr. Orwin served in various executive level positions at Johnson & Johnson. He served in Johnson & Johnson's Ortho Biotech division, where he served as Franchise Vice President, Oncology of the Tibotec Therapeutics group. He has held Senior Marketing and Sales Positions with Schering-Plough Corporation, Rhone-Poulenc Rorer Pharmaceuticals, Sangstat Medical Corporation and Alza Pharmaceuticals. Mr. Orwin was Senior Director, Oncology Marketing at ALZA Pharmaceuticals, Vice President, Marketing at Sangstat Medical Corporation; Marketing Director, Asthma at Rhone-Poulenc Rorer Pharmaceuticals and Product Manager, Schering Oncology/Biotech at Schering-Plough Corporation. He served as the Chairman of Affymax, Inc. from June 6, 2013 to November 2014. He has an Independent Director of Retrophin, Inc. since March 23, 2017. He serves as Director of Biotechnology Innovation Organization. He served as an Independent Director of Array BioPharma Inc. since November 6, 2012 until July 30, 2019. He has been an Independent Director of NeurogesX, Inc. since November 19, 2009. He has been a Director and a Member of Emerging Companies Section Governing Board at Biotechnology Industry Organization since July 2011. He served as a Director of Affymax, Inc. from February 1, 2011 to November 2014. Mr. Orwin holds a Master of Business Administration from the Stern School of Business, New York University and a Bachelor of Arts Degree in Economics from Rutgers University.

CEO Compensation
  • Insufficient data for John to compare compensation growth.
  • John's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Atreca management team in years:

2
Average Tenure
54
Average Age
  • The tenure for the Atreca management team is about average.
Management Team

John Orwin

TITLE
President
COMPENSATION
$5M
AGE
54
TENURE
2 yrs

Tito Serafini

TITLE
Co-Founder
COMPENSATION
$3M
AGE
56

Norm Greenberg

TITLE
Chief Scientific Officer
COMPENSATION
$801K
AGE
59
TENURE
4.9 yrs

Herb Cross

TITLE
Chief Financial Officer
AGE
47
TENURE
1.2 yrs

Yann Tan

TITLE
Chief Technologist

Guy Cavet

TITLE
Chief Technical Officer
AGE
45
TENURE
5.8 yrs

Wayne Volkmuth

TITLE
Senior Vice President of Informatics and Information Technology

Courtney Phillips

TITLE
General Counsel & Corporate Secretary
TENURE
0.8 yrs

Daniel Emerling

TITLE
Senior Vice President of Research

Jonathan Woo

TITLE
Senior Vice President of Finance & Strategy
Board of Directors Tenure

Average tenure and age of the Atreca board of directors in years:

3
Average Tenure
61
Average Age
  • The average tenure for the Atreca board of directors is less than 3 years, this suggests a new board.
Board of Directors

Brian Atwood

TITLE
Chairman of the Board
COMPENSATION
$35K
AGE
66
TENURE
6.3 yrs

John Orwin

TITLE
President
COMPENSATION
$5M
AGE
54
TENURE
2 yrs

Tito Serafini

TITLE
Co-Founder
COMPENSATION
$3M
AGE
56

Larry Steinman

TITLE
Chairman of External Scientific Advisory Board & Technical Advisor
COMPENSATION
$150K
AGE
71
TENURE
0.7 yrs

Franklin Berger

TITLE
Independent Director
COMPENSATION
$25K
AGE
70
TENURE
5.5 yrs

David Lacey

TITLE
Independent Director
COMPENSATION
$25K
AGE
67
TENURE
3.9 yrs

Bill Robinson

TITLE
Director
COMPENSATION
$250K
AGE
51

Douglas Crawford

TITLE
Board Observer

Andrew Farnum

TITLE
Board Observer

Lindsey Rolfe

TITLE
Director
AGE
51
TENURE
0.7 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Atreca individual insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
19. Mar 20 Buy John Orwin Individual 17. Mar 20 17. Mar 20 6,000 €11.65 €69,872
X
Management checks
We assess Atreca's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Atreca has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

0C1 News

Simply Wall St News

0C1 Company Info

Description

Atreca, Inc., a biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody in preclinical development with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company’s ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. It has a research collaboration agreement with Serimmune, which applies serum epitope repertoire analysis platform that maps the antigenic targets of antibody repertoires to identify the targets of selected therapeutic antibody candidates for oncology generated by the company; and a strategic research collaboration with Merck to identify the antigenic targets of select antibodies discovered with potential utility in oncology. Atreca, Inc. was founded in 2010 and is headquartered in Redwood City, California.

Details
Name: Atreca, Inc.
0C1
Exchange: DB
Founded: 2010
$358,786,231
28,071,088
Website: http://www.atreca.com
Address: Atreca, Inc.
500 Saginaw Drive,
Redwood City,
California, 94063,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS BCEL Class A Common Stock Nasdaq Global Select US USD 20. Jun 2019
DB 0C1 Class A Common Stock Deutsche Boerse AG DE EUR 20. Jun 2019
MUN 0C1 Class A Common Stock Boerse Muenchen DE EUR 20. Jun 2019
Number of employees
Current staff
Staff numbers
113
Atreca employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/08 00:16
End of day share price update: 2020/04/07 00:00
Last estimates confirmation: 2020/03/18
Last earnings filing: 2020/03/11
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.